Tyrosine Kinase Inhibitors
Treatment options for brain metastases in patients with EGFR-mutant NSCLC include SRS, WBRT, and EGFR TKIs. In this study, researchers sought to determine the optimal treatment approach of those who develop brain metastases and have not received EFGR TKIs.
Ceritinib is a kinase inhibitor indicated for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib; in this study, researchers determined the efficacy of ceritinib in patients with untreated ALK-rearranged NSCLC.
A review of adverse effects and recommended management for 3 kinase inhibitors indicated for the treatment of gastrointestinal cancers.
Patients with chronic lymphocytic leukemia (CLL) who discontinue TKI therapy due to toxicity can successfully be treated with an alternate TKI.
The addition of vandetanib to a platinum agent and etoposide did not improve time to progression or overall survival in patients with newly diagnosed extensive-stage SCLC.
Patients with medullary thyroid cancer who harbor RET M918T or RAS mutations may derive greater clinical benefit from cabozantinib compared with patients who do not have those genetic mutations.
Patients with metastatic non-small cell lung cancer demonstrated prolonged median progression-free survival with the administration of erlotinib below the maximum tolerated dose.
Presence of certain microRNAs (miRNAs) is predictive of response to TKIs and prognosis for patients with metastatic renal cell carcinoma (mRCC).
For patients with chronic myeloid leukemia treated with lifelong targeted therapies, social support is crucial for maintaining psychological well-being.
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) plus ponatinib appears to be superior to hyper-CVAD plus dasatinib for the frontline treatment of patients with Philadelphia chromosome-positive ALL.
Cobimetinib in combination with vemurafenib as a standard first-line approach improves survival in patients with BRAF V600 mutation-positive melanoma, updated results of the coBRIM study.
Tyrosine Kinase Inhibitor Therapy Can Be Safely Stopped in Select Patients With CML in Chronic PhaseJuly 29, 2016
A high percentage of patients with CML treated with TKIs achieve deep molecular responses and can safely stop therapy. Initials results of the EURO-SKI trial define prognostic markers that indicate durability of deep molecular responses after stopping TKI therapy.
Scientists discovered the compound eCF506. This compound was more effective than existing medicines at targeting breast cancer cells because it more selectively inhibited SRC tyrosine kinase.
Treatment Compliance and Severe Adverse Events Limit the Use of Tyrosine Kinase Inhibitors in Refractory Thyroid CancerOctober 29, 2015
[OncoTargets and Therapy] This research examines patient compliance with tyrosine kinase inhibitor (TKI) treatment for refractory and progressive thyroid cancer, as well as exploring the efficacy and serious adverse events associated with this treatment.
Increased risk of Severe Infections in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Meta-AnalysisSeptember 29, 2015
[OncoTargets and Therapy] This research examines the risks and benefits associated with using small-molecule vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs).
Afatinib is clinically active and well tolerated in many tyrosine kinase inhibitor (TKI)-pretreated patients with non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations, according to a new study.
A new tool predicts what genetics are truly driving the cancer in any population of cells and helps the user choose the best kinase inhibitor to address the issue.
[Breast Cancer: Targets and Therapy] This research reviews the preclinical as well as clinical data on neratinib.
What data are available concerning inter- and intrapatient variability in the pharmacokinetics of TKIs in chronic myeloid leukemia?
Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side effects in patientsOctober 24, 2014
A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).
IMPRESS trial fails to find benefit from more tyrosine kinase inhibitor (TKI) treatment after resistance developsOctober 17, 2014
Patients with lung cancer that have developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival when continued use of the drug with chemotherapy is utilized.
Many young adults with the most common form of acute lymphoblastic leukemia (ALL) have a high-risk subtype with a poor prognosis and could benefit from drugs used to treat other types of leukemia.
EGFR inhibitors are widely used to treat metastatic NSCLC; however, they can cause various adverse effects that differ from those caused by traditional intravenous chemotherapy.
Is pazopanib (Votrient) approved for the treatment of leiomyosarcoma?
Using advanced genetics technologies to monitor for remaining cancer cells after treatment may soon become an effective tool to inform treatment decisions for acute lymphocytic leukemia patients.
Testosterone levels were below the lower limit of normal in 84% of men undergoing crizotinib therapy for the treatment of lung cancer.
Ponatinib (Iclusig), bosutinib (Bosulif), and omacetaxine (Synribo) are enhancing treatment for persons with certain forms of leukemia.
EGFR mutation is not a prognostic factor in non-small cell lung cancer, but EGFR tyrosine kinase inhibitors may prolong survival after recurrence.
Interim results confirmed the "unprecedented" single-agent activity of ibrutinib in relapsed or refractory mantle cell lymphoma.
Leukemia stem cells that overcome drug therapy can be thwarted when deprived of RAD52, a protein key to DNA repair of these cancer cells.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|